Microsoft and PAREXEL announced a technology development alliance aimed at driving innovation across the life sciences industry with technology powered by Microsoft Azure.
The collaboration between Microsoft and PAREXEL is designed to help the industry accelerate drug development. The companies will combine Microsoft's global cloud infrastructure, intelligent services, and research and development capabilities with PAREXEL's global presence and its clinical and regulatory technology domain expertise.
The partnership will be initially focused on moving PAREXEL Informatics technology and services onto Microsoft Azure, making it the preferred secure cloud platform for PAREXEL's technology offerings. Microsoft and PAREXEL will also jointly develop innovative, patient-centric technologies and cloud-based services to support clinical research and market access for global life science clients.
"Technology is disrupting the established model of research and development in health care," said Xavier Flinois, president, PAREXEL Informatics. "Drug development is becoming more complex, while innovations including social media, analytics, mobile technology and the Internet of Things are enabling a more patient-centric approach. In combination, Microsoft's leading innovations and commitment to security and regulatory compliance, along with PAREXEL's industry expertise, will allow us to bring accelerated drug delivery timelines and improved patient engagement to the industry."
Microsoft Azure is an open, flexible, enterprise-grade cloud computing platform and set of services. PAREXEL Informatics provides technology solutions to help optimize patient engagement, clinical and regulatory processes.